Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Endoscopic treatment outcome of oesophageal gastrointestinal stromal tumours
En-Pan Xu, Zhi-Peng Qi, Jia-Wei Zhang, Bing Li, Zhong Ren, Ming-Yan Cai, Shi-Lun Cai, Zhen-Tao Lv, Zhang-Han Chen, Jing-Yi Liu, Yun-Shi Zhong, Ping-Hong Zhou, Qiang Shi
En-Pan Xu, Zhi-Peng Qi, Bing Li, Zhong Ren, Ming-Yan Cai, Shi-Lun Cai, Zhen-Tao Lv, Zhang-Han Chen, Jing-Yi Liu, Yun-Shi Zhong, Qiang Shi, Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China
En-Pan Xu, Department of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo 315000, Zhejiang Province, China
Jia-Wei Zhang, Endoscopy Center, Shanghai Xuhui District Central Hospital, Shanghai 200030, China
Ping-Hong Zhou, Endoscopy Center and Endoscopy Research Institute, Shanghai Collaborative Innovation Center of Endoscopy, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Co-first authors: En-Pan Xu and Zhi-Peng Qi.
Author contributions: Shi Q, Zhong YS, and Zhou PH designed the research study; Xu EP, Qi ZP, Zhang JW, Li B, Ren Z, Cai MY, Cai SL, Lv ZT, Chen ZH, Liu JY, Zhong YS, and Zhou PH performed the research; All authors have read and approve the final manuscript.
Supported by National Natural Science Foundation of China, No. 82002515, No. 82273025 and No. 82203460; China Postdoctoral Science Foundation, No. 2022TQ0070 and No. 2022M710759; and Shanghai Municipal Commission of Science and Technology, No. 22JC1403003, No. 22XD1402200, No. 19140901902 and No. 22S31903800.
Institutional review board statement: The Committee of Medical Ethics (Zhongshan Hospital Fudan University, No. B2020-265R) approved this study.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data that support the findings of this study are available from the corresponding author, upon reasonable request at
shi.qiang@zs-hospital.sh.cn.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Qiang Shi, MD, Associate Chief Physician, Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai 200032, China.
shi.qiang@zs-hospital.sh.cn
Received: October 16, 2024
Revised: January 4, 2025
Accepted: February 8, 2025
Published online: March 14, 2025
Processing time: 132 Days and 19.6 Hours
BACKGROUND
There are few clinicopathologic characteristics and clinical results for oesophageal gastrointestinal stromal tumours (GISTs). Thus, the objective of this study was to identify the clinicopathologic characteristics and clinical results of oesophageal GISTs.
AIM
To investigate endoscopic treatment effective of oesophageal GISTs.
METHODS
It was retrospective research that collected 32 patients with oesophageal GISTs treated by endoscopic resection (ER) between January 2012 and January 2023 in two Hospital. Clinicopathologic, endoscopic records, and follow-up data were collected and analysed.
RESULTS
Thirty-one patients underwent en bloc resection and 24 (75.0%) lesions underwent R0 resection. The size of GISTs was 2.12 ± 1.88 cm. The overall complication rate was 25.0%, including hydrothorax and post-endoscopic submucosal dissection electrocoagulation syndrome. The mean mitotic index was 3.34 ± 5.04 (median, 1.50; range, 1.00-4.00). Eighteen (56.3%), 6 (18.8%), 2 (6.3%), and 6 (18.8%) patients were identified as very low, low, intermediate, and high risk, respectively. Three patients developed recurrence after a median follow-up of 64.69 ± 33.13 months. The 5-year overall survival rate was 100%, and the disease-free survival rate was 90.6%.
CONCLUSION
ER is safe and effective for patients with low-risk oesophageal GISTs. Early detection of oesophageal GISTs is essential to achieve a favourable prognosis.
Core Tip: Oesophageal gastrointestinal stromal tumours are extremely rare. Endoscopic resection proves to be both safe and effective for patients with low-risk. Early detection plays a critical role in determining the prognosis of these tumours.
